Dirk Thye, President and CEO

Dirk Thye, M.D., brings approximately 20 years of drug development executive experience to Agenovir. Most recently, he served as Chief Medical Officer of Cidara, Inc., building and managing all aspects of drug development including the filing of several Investigational New Drug (“IND”) applications and advancement of two programs into Phase 2 clinical trials. In addition, he was instrumental in helping the company raise approximately $150 million over a one year period through multiple private financings and an initial public offering. Previously, he co-founded Cerexa and served as President for the last several years of his tenure, following the acquisition by Forest Laboratories. While at Cerexa, he led the development of ceftaroline (Teflaro®) from pre-IND to New Drug Application filing, FDA Advisory Committee and approval, and played a key role in the evaluation and acquisition of avibactam, a beta-lactamase inhibitor from Novexel, leading the joint development committee on behalf of Forest Laboratories in partnership with AstraZeneca. Avibactam in combination with ceftazidime (Avycaz®) was approved by the FDA in February 2015. Prior to Cerexa, Dr. Thye was a Founder and Senior Vice President of Clinical Development for Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005), a company that developed doripenem (Doribax®) for severe bacterial infections in hospitalized patients. Dr. Thye has participated as a member of the board of directors or scientific advisory board member for several companies in the anti-infective area. He received his B.A. in Molecular Biology from UC Berkeley, his M.D. from UCLA, and completed his residency in Internal Medicine at Stanford University.

Bolyn Hubby, Chief Scientific Officer

Bolyn Hubby, Ph.D., brings over 15 years of industry expertise driving innovative technologies into the clinic to address unmet needs in infectious disease and oncology. Dr. Hubby joins Agenovir from Synthetic Genomics, where she was most recently vice president of vaccines and antimicrobials research and development, working with partner Novartis to transition the company’s core synthetic biology technology for influenza vaccines into clinical studies. In addition, Dr. Hubby and her team developed novel RNA vaccine and antimicrobial platforms to address the rapid spread of infectious disease and the growing global threat of antibiotic resistance. Prior to Synthetic Genomics, Dr. Hubby served as executive director of vaccines at Liquidia Technologies, Inc., where she and her team built a portfolio of programs focused on new approaches to protein, polysaccharide, and RNA-vectored vaccines targeting bacterial and viral pathogens. Before Liquidia, Dr. Hubby was head of discovery immunology at AlphaVax, Inc., where she helped advance a unique RNA-based viral vector to develop vaccines for infectious diseases, biodefense and cancer. Dr. Hubby is an author on numerous issued and pending patents as well as over 20 peer-reviewed publications. She received her Ph.D. in cellular biology from the University of Georgia.

Derek Sloan, Director, Research

Derek Sloan, M.D., joined Agenovir as the Director of Research in October 2015, bringing over 17 years of post-graduate research experience in the fields of virology, immunology, and cancer cell biology. Most recently, he served as Senior Scientist at Gilead Sciences, where he led a biology discovery team involved in the HIV Cure program. Prior to Gilead, he served in escalating scientific management roles at MedImmune and Immune Design, where he led and advanced herpes simplex vaccine programs. Before moving to industry, Dr. Sloan served on the faculty of the University of Washington School of Medicine. He earned his M.D. from the UC San Diego and his B.A. in Immunology and Microbiology from UC Berkeley.